Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company’s AI-enabled Drug Development Strategy PHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

Molecularly targeted therapies are increasingly relevant in clinical oncology, as they enable the selective modulation of specific biologic targets—such as enzymes or receptors—by inhibiting or ...

Stage and screen actor Robert Lindsay, 76, is the 100,000th signature to the petition calling for prostate cancer screening ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

MDT associated with improved progression-free, radiographic progression-free, castration resistance-free survival.

Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.F ...

Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth quarter 2025 gross margin ...

Radiopharmaceuticals therapy (RPT) has been a major breakthrough in the treatment of prostate cancer. This therapy utilizes radioactive isotopes targeted specifically to prostate cancer, combining the ...

Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ...

3-in-1 therapies (compression, vibration, and LED) to optimize recovery. Features preset routines and customizable settings. Fully wireless. Available in three sizes. Limited transparency around the ...

Prostatic stromal sarcoma (PSS) is a rare malignant mesenchymal tumor originating from the specialized stroma of the prostate. It is a heterogeneous tumor, in which a predominantly phyllodes ...